Login to Your Account



Abide with Me: Merck Paying up to $430M in Diabetes Deal

By Randy Osborne
Staff Writer

Thursday, May 2, 2013
Abide Therapeutics Inc.'s potential $430 million deal with Merck & Co. Inc. is focusing on Type II diabetes by way of small molecules that take aim at members of the serine hydrolase enzyme family.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription